PubMed COVID-19 Clinical Care

Favipiravir is a potential antiviral drug undergoing clinical trials to manage various viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Favipiravir possesses antiviral properties against RNA viruses, including

A 60-year-old woman with a past medical history of asthma presented with fulminant myocarditis 9 days after testing positive for SARS-CoV-2 and 16 days after developing symptoms consistent with COVID-19. Her hospital course was complicated by the

No abstract

This literature review described the genetic and biochemical factors that may have been overlooked in the formulation of vaccines and that most likely underlie possible issues with mass vaccination.

It seems as though progressively more people are in the race to upload content, data, and information online; and hospitals haven't neglected this trend either. Hospitals are now at the forefront for multi-site medical data sharing to provide ground

Since the beginning of the COVID-19 pandemic in early 2020, global efforts to respond to and control COVID-19 have varied widely with some countries, including Australia, successfully containing local transmission, and minimising negative impacts to

The current pandemic of Severe Acute Syndrome (SAR-CoV-2) is a public health problem with implications for mental health. The study aimed to determine the prevalence of suicide risk and its association with fatalism and emotional regulation during

The wide spread of coronavirus pneumonia (COVID-19) has been a severe threat to global health since 2019. Apart from the nucleic acid detection, medical imaging examination is a vital diagnostic modality to confirm and treat the disease. Thus

Seated stability is a major concern of individuals with trunk paralysis. Trunk paralysis is commonly caused by spinal cord injuries (SCI) at or above the thoracic spine. Current methods to improve stability restrict the movement of the user by

CONCLUSION: The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity.